PURPOSE: Genetic factors are important in the etiology and pathogenesis of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). Only a few small studies have assessed clinical characteristics and prognosis for familial patients, with inconsistent findings. METHODS: Using population-based registries from Sweden and Denmark, 7,749 patients with CLL, 7,476 patients with HL, and 25,801 patients with NHL with linkable first-degree relatives were identified. Kaplan-Meier curves were constructed to compare survival in patients with lymphoma with and without a family history of lymphoma. The risk of dying was assessed using adjusted Cox proportional hazard models. RESULTS: We found 85 patients with CLL (1.10%), 95 patients with HL (1.28%), and 206 patients with NHL (0.80%) with a family history of any lymphoma. Five-year mortality was similar for patients with CLL (hazard ratio [HR], 1.28; 95% CI, 0.95 to 1.72), HL (HR, 0.78; 95% CI, 0.49 to 1.25), and NHL (HR, 0.91; 95% CI, 0.74 to 1.12) versus without a family history of any lymphoma. Mortality was also similar for patients with versus without a family history of the same lymphoma. T-cell/anaplastic lymphoma patients with a family history of NHL had poorer outcome 5-years after diagnosis (HR, 5.38; 95% CI, 1.65 to 17.52). Results were similar for 10 years of follow-up. CONCLUSION: With the exception of T-cell/anaplastic lymphoma, survival patterns for patients with CLL, HL, and NHL with a family history of lymphoma were similar to those for sporadic patients, suggesting that most familial lymphomas do not have an altered clinical course. Our findings provide no evidence to modify therapeutic strategies for patients with CLL, HL, or NHL based solely on family history.
PURPOSE: Genetic factors are important in the etiology and pathogenesis of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). Only a few small studies have assessed clinical characteristics and prognosis for familial patients, with inconsistent findings. METHODS: Using population-based registries from Sweden and Denmark, 7,749 patients with CLL, 7,476 patients with HL, and 25,801 patients with NHL with linkable first-degree relatives were identified. Kaplan-Meier curves were constructed to compare survival in patients with lymphoma with and without a family history of lymphoma. The risk of dying was assessed using adjusted Cox proportional hazard models. RESULTS: We found 85 patients with CLL (1.10%), 95 patients with HL (1.28%), and 206 patients with NHL (0.80%) with a family history of any lymphoma. Five-year mortality was similar for patients with CLL (hazard ratio [HR], 1.28; 95% CI, 0.95 to 1.72), HL (HR, 0.78; 95% CI, 0.49 to 1.25), and NHL (HR, 0.91; 95% CI, 0.74 to 1.12) versus without a family history of any lymphoma. Mortality was also similar for patients with versus without a family history of the same lymphoma. T-cell/anaplastic lymphomapatients with a family history of NHL had poorer outcome 5-years after diagnosis (HR, 5.38; 95% CI, 1.65 to 17.52). Results were similar for 10 years of follow-up. CONCLUSION: With the exception of T-cell/anaplastic lymphoma, survival patterns for patients with CLL, HL, and NHL with a family history of lymphoma were similar to those for sporadic patients, suggesting that most familial lymphomas do not have an altered clinical course. Our findings provide no evidence to modify therapeutic strategies for patients with CLL, HL, or NHL based solely on family history.
Authors: O Paltiel; T Schmit; B Adler; E A Rachmilevitz; A Polliack; A Cohen; N Haim; M B Shachar; R Epelbaum; M Barchana; R Cohen; D Ben Yehuda Journal: Cancer Date: 2000-05-15 Impact factor: 6.860
Authors: Mark P Purdue; Qing Lan; Anne Kricker; Andrew E Grulich; Claire M Vajdic; Jennifer Turner; Denise Whitby; Stephen Chanock; Nathaniel Rothman; Bruce K Armstrong Journal: Carcinogenesis Date: 2006-10-20 Impact factor: 4.944
Authors: Je-Jung Lee; Dong Hwan Kim; Nan Young Lee; Sang Kyun Sohn; Jong Gwang Kim; Hyeoung-Joon Kim; Young Rok Do; Yeon Hee Park Journal: Br J Haematol Date: 2007-04-04 Impact factor: 6.998
Authors: Ingemar Turesson; Martha S Linet; Magnus Björkholm; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Ola Landgren Journal: Int J Cancer Date: 2007-11-15 Impact factor: 7.396
Authors: Alyssa I Clay-Gilmour; Abdul R Rishi; Lynn R Goldin; Alexandra J Greenberg-Worisek; Sara J Achenbach; Kari G Rabe; Matthew J Maurer; Neil E Kay; Tait D Shanafelt; Timothy G Call; J Brice Weinberg; Nicola J Camp; James R Cerhan; Jose Leis; Aaron Norman; David L Murray; S Vincent Rajkumar; Neil E Caporaso; Ola Landgren; Mary L McMaster; Susan L Slager; Celine M Vachon Journal: Blood Cancer J Date: 2019-08-05 Impact factor: 11.037
Authors: Fredrik Baecklund; Sara Ekberg; Richard Rosenquist; Johan Askling; Sandra Eloranta; Karin E Smedby Journal: Eur J Haematol Date: 2020-09-29 Impact factor: 2.997